Initial staging of hodgkin's disease: Role of contrast-enhanced 18F FDG PET/CT

Medicine (United States)

Volumn 93, Issue 8, 2014, Pages

  Chiaravalloti, Agostino ^a   Danieli, Roberta ^a   Caracciolo, Cristiana Ragano ^a   Travascio, Laura ^a   Cantonetti, Maria ^a   Gallamini, Andrea ^b   Guazzaroni, Manlio ^a   Orlacchio, Antonio ^a   Simonetti, Giovanni ^a   Schillaci, Orazio ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Ospedaliera S Coce e Carle   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; NONIONIC CONTRAST MEDIUM; VINBLASTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; ATTENUATION; BIOPSY; BONE MARROW METASTASIS; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; SPLEEN METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; IMAGE QUALITY; METHODOLOGY; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906083515     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000050     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26:5170-5174.
3. Johnson PW. Management of early-stage Hodgkin lymphoma: is there still a role for radiation?Hematology Am Soc Hematol Educ Program. 2013;400.
4. Borchmann P. Early intensification treatment approach in advancedstage Hodgkin lymphoma. Hematol Oncol Clin North Am. 2014;28:65-74.
5. Borchmann P, Andreas EA. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program. 2010;2010:101-107.
6. Domnguez AR, Marquez A, Guma J, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol. 2004;15:1798-1804. (Pubitemid 40012246)
7. Enger A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640-652.
8. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18:376-380. (Pubitemid 46323108)
9. Owadally WS, Sydes MR, Radford JA, et al. Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol. 2010;21:568-573.
10. Chiaravalloti A, Pagani M, Di Pietro B, et al. Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? Nucl Med Commun. 2013;34:57-63.
11. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636. (Pubitemid 19272832)
12. Bednaruk-Mlynski E, Pienkowska J, Skorzak A, et al. The comparison of PET/CT with classical contrast-enhanced CT in the initial staging of Hodgkin lymphoma. Leuk Lymphoma. 2014;2:2.
13. Di Paul S, Townsend DW. PET-CT imaging of lymphoma. In: Di Paul S, Townsend DW, eds. Clinical PET-CT in Radiology: Integrated Imaging in Oncology. Springer; 2011:267-295.
14. Haerle SK, Strobel K, Ahmad N, et al. Contrast-enhanced 18F-FDGPET/ CT for the assessment of necrotic lymph node metastases. Head Neck. 2011;33:324-329.
15. Tateishi U, Maeda T, Morimoto T, et al. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:1627-1634. (Pubitemid 47476922)
16. Chu MM, Kositwattanarerk A, Lee DJ, et al. FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma. Radiographics. 2010;30:1353-1372.
17. Picardi M, Soricelli A, Grimaldi F, et al. Fused FDG-PET/contrastenhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol. 2011;22:671-680.
18. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007;48:19-27.
19. Pinilla I, Gomez-Leon N, Del Campo-Del Val L, et al. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. Q J Nucl Med Mol Imaging. 2011;55:567-575.
20. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47:1643-1648. (Pubitemid 47545030)
21. Harris NL, Jaffe ES, Diebold J, et al. Lymphoma classification - from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 2000; 11(Suppl 1):3-10.
22. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;20:20.
23. Werko L. [Ethics committees bear a responsibility for patient information. Informed consent implies that the patient understands what he has consented to]. Lakartidningen. 2002;99:1552-1555.
24. Chiaravalloti A, Danieli R, Abbatiello P, et al. Factors affecting intrapatient liver and mediastinal blood pool F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2014;22:22.
25. Alessandrini M, Pagani M, Napolitano B, et al. Early and phasic cortical metabolic changes in vestibular neuritis onset. PLoS One. 2013;8:7.
26. Schillaci O, Travascio L, Bolacchi F, et al. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med. 2009;114:890-906.
27. Gossmann A, Eich HT, Engert A, et al. CT and MR imaging in Hodgkin's disease - present and future. Eur J Haematol Suppl. 2005;66:83-89. (Pubitemid 40873983)
28. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med. 2004;34:122-133. (Pubitemid 38375467)
29. Antoch G, Jentzen W, Freudenberg LS, et al. Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol. 2003;38:784-789. (Pubitemid 37444951)
30. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608-613. (Pubitemid 41716405)
31. Pfannenberg AC, Aschoff P, Brechtel K, et al. Value of contrastenhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol. 2007;80:437-445. (Pubitemid 47322230)
32. Wu TH, Huang YH, Lee JJ, et al. Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging. 2004;31:38-43. (Pubitemid 38133539)
33. Morimoto T, Tateishi U, Maeda T, et al. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: comparison of integrated PET/CT with or without contrast enhancement. Eur J Radiol. 2008;67:508-513.
34. Histed SN, Lindenberg ML, Mena E, et al. Review of functional/ anatomical imaging in oncology. Nucl Med Comm. 2012;33:349-361.
35. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643-4651. (Pubitemid 46224066)
36. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340-3346. (Pubitemid 28193885)